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INTRODUCTION
        Ovarian tumors are rare accounting for 1% of childhood malignancies. Unlike adult 
tumors, two thirds of the pediatric ovarian malignancies are of germ cell origin. Tumors 
of  epithelial  and stromal  origin occur  less  frequently.  As with testicular  tumors,  the 
incidence  of  germ  cell  ovarian  tumors  parallel  gonadotrophin  release  implicating 
hormonal factors in the aetiology.
                   The prognosis and the treatment strategies for malignant pediatric tumors 
have also changed drastically over the last few years. The outlook was dismal in the pre-
chemotherapy era. But with the advent of platinum based chemotherapy in the 1980s, 
the prognosis for these tumors has altered dramatically. It has also facilitated the re-
definition  of  risk  groups.  Since  then,  chemotherapy  regimes  have  been  sequentially 
modified to reduce the toxicity while maintaining survival rates.
                 Surgical approach has also evolved to a more tailored approach.
                 As we move into the future, with higher success rates in the overall survival,  
the highlight is now on reducing the toxicity of the chemotherapy regimes. Ongoing 
studies are now evaluating conservative surgeries in the hope of reducing the overall 
morbidity.  An  attempt  is  being  made  to  redefine  surgical  principles  in  the  hope  of 
improving the quality of life without compromising the overall survival.
                      With more survivors of childhood cancer, interest is now being focused on 
the delayed effects on treatment and its impact on potential fertility patterns. More stress 
is  now being  laid  on  maintaining  the  reproductive  abilities  of  these  patients  and  a 
number of studies are ongoing in this direction.
=
AIMS & OBJECTIVES
• To review the presentation, treatment and histology of ovarian tumors in children.
• To note the accuracy of diagnostic imaging and operative staging .
• To calculate the survival rates.
• To assess  the effect  of  chemotherapy on the attainment  of  menarche in  those 
surviving in the peripubertal age group.
REVIEW OF LITERATURE
                   Gynecological lesions account for 2% of childhood cancers23. Of these, 
60% - 70% arise in the ovary. The concept that the incidence of malignancy was 
higher in the young has now been revisited. In a 43 year review, Gibbon et al13 
noted that malignant ovarian tumors were more frequent in the second decade.
              The North American Cancer Registries report released in 1993 revealed that 
1.2% of ovarian cancers occurred between birth and 9 years.33
                       Due to this rarity of ovarian tumors in children, earlier approaches to 
management were based on the guidelines from review of adult literature. But, 
with widening of our knowledge of cancer biology, realization has now dawned 
that children are not just ‘miniature’ adults.  The juvenile forms of the disease 
represent distinct entities, which often present at a less advanced stage and have a 
more favorable natural history and response to therapy. 
W.H.O. CLASSIFICATION OF OVARIAN TUMORS
1. Surface epithelial stromal tumors
        1.1. Serous tumors
        1.2. Mucinous tumors
        1.3. Endometroid tumors
        1.4. Clear cell tumors
        1.5. Transitional cell tumors
        1.6. Squamous cell tumors
        1.7. Mixed epithelial tumors
        1.8. Undifferentiated and unclassified tumors   
     2. Sex cord-stromal tumors
        2.1. Granulosa – stromal cell tumors
               2.1.1 Granulosa cell tumor group
                         2.1.1.1. Adult 
                         2.1.1.2. Juvenile
               2.1.2. Tumors in the thecoma – fibroma group
        2.2. Sertoli-stromal cell tumors
        2.3. Sex cord – stromal tumors (mixed or unclassified)  
               2.3.1. Sex cord tumors with annular tubules
               2.3.2. Gynandroblastoma
        2.4. Steroid cell tumors
3. Germ cell tumors 
    3.1. Primitive germ cell tumors
           3.1.1. Dysgerminoma
           3.1.2. Yolk sac ( endodermal sinus) tumor
           3.1.3. Embryonal carcinoma
           3.1.4. Polyembryoma
           3.1.5. Non gestational choriocarcinoma
           3.1.6. Mixed germ cell tumors
     3.2. Biphasic or triphasic teratomas
            3.2.1. Immature
             3.2.2. Mature
     3.3 Monodermal teratomas
  4. Germ cell sex-cord-stromal tumors
     4.1. Gonadoblastoma
     4.2. Mixed germ cell sex-cord stromal tumor (non  gonadobastoma  origin)  
 5. Tumors of rete ovarii
 6. Miscellaneous tumors
    6.1. Small cell carcinomas, hypercalcemic type
    6.2. Gestational choriocarcinomas
    6.3. Soft tissue tumors non specific to the ovary
7. Tumor like conditions
8. Lymphoid and haemopoietic tumors
9. Secondary tumors
GERM CELL TUMORS
EMBRYOGENESIS & HISTOGENESIS
                    Germ cell tumors share a common cell of origin-the primordial germ cell, 
yet they remain a heterogeneous group with variations in age, site of presentation and 
histopathology. This stems from the differences in the stage of germ cell development at 
tumorigenesis.
                      Primordial germ cells are first evident in the extra-embryonic yolk sac by 
the IVth week of gestation. These migrate through the mesentry to the gonadal  ridge, a 
process that is mediated by the c-kit receptor and its ligand, the stem cell factor.
                     The current model for germ cell development resulted from the work of 
Dixon and Moore (1952), Teilum(1976)and Mostofi (1973).These totipotent germ cells 
can travel down normal differentiation pathways and become oocytes. However, if these 
germ cells travel down abnormal pathways, dysgerminomas or embryonal carcinomas 
(totipotent tumor cells) can occur. If the embryonal cells undergo further differentiation 
along intraembryonic pathways, teratomas result. Extraembryonic differentiation results 
in a yolk sac tumor or a choriocarcinoma. This model explains the tumor markers 
produced by certain tumor types. Endodermal sinus tumors produce alpha fetoprotein 
just like the fetal yolk sac. Likewise, choriocarcinoma produces human chorionic 
gonadotrophin just like the normal placenta. 
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TUMORIGENIC MODEL FOR GERM CELL TUMORS
GERM CELL TUMORS
                     Germ cell  tumors are probably the most  varied of all  pediatric 
malignancies.  They  account  for  3%  of  childhood  cancers12.They  show  a  bimodal 
distribution in infancy and during adolescence. As they arise from a common totipotent 
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progenitor,  it  is  possible to have a wide variety of histologies co-existing within the 
same tumor.25% have multiple histologic components12.Co-existing elements of benign 
teratoma are particularly common in the mediastinal and ovarian locations4.
                      The classification of immature teratomas as benign or malignant still 
remains a matter of debate. These tumors are graded by the neuroepithelial elements that 
they contain. There is always the remote possibility of missing malignant elements in 
large tumors. A review of the pathology of immature teratomas between 1990 to 1995 
by the Pediatric Oncology Group and the Children’s Cancer Study Group documented 
increased  risk  of  high  grade  immaturity  with  the  presence  of  microscopic  foci  of 
endodermal sinus tumor. This was noted in as many as 83% of the specimens and was 
the  only  important  risk  factor  for  recurrence  in  immature  teratomas  at  all  sites  and 
ages15.Thus, high grade immature teratomas are often included in the malignant germ 
cell category and treated with chemotherapy2.
CLINICAL FEATURES:
                    Clinical presentations do not differentiate between benign and malignant 
tumors. Abdominal pain is the most frequent symptom7. It may be acute with a crescendo 
pattern  as  in  torsion.  Such  situations  commonly  lead  to  the  mistaken  pre-operative 
diagnosis of appendicitis in a right sided lesion. Some have a more insidious onset of 
pain  with  distension  developing  over  time.  Other  symptoms  include  nonspecific 
anorexia,  nausea,  vomiting  or  urinary  frequency  and  urgency  if  compression  of  the 
pelvic organs occur.
                   Endocrine activity is seen in 10% of cases17 and may cause precocious 
puberty. This is due to the production of HCG, most commonly associated in patients 
with  dysgerminomas,  endodermal  sinus  tumors  and  choriocarcinomas,  though  more 
frequently in sex cord tumors.
                   Virilisation due to androgen excess occurs in endodermal sinus tumors, 
Sertoli-Leydig cell tumors and dysgerminomas in older children .
CLINICAL FEATURES OF PAEDIATRIC OVARIAN TUMORS
TUMOR TYPE MEDIAN 
AGE 
RELATIVE 
FREQUENCY
FEATURES
Dysgerminoma 16yrs. 24% Rapidly  developing, 
14-25% with other germ 
cell elements. Extremely 
radiosensitive.
Teratoma 11-14 yrs. 10-30% Grading system based on 
amountof neuroepithelial 
elements,prognosis 
varies  inversely  with 
stage  and  grade, 
30% have raised AFP
Mixed  malignant 
germ cell tumors
16 yrs    11% 40% premenarchal,  30% 
sexually  precocious,AFP 
and HCG may be raised.
Gonadoblastoma 8-10 yrs   1% Associated  with 
dysgenetic  gonads  and 
gonadal 
maldevelopment. 
Removal of both gonads 
is treatment of choice.
Others:
choriocarcinoma,
polyembryoma
NA <1% Rare in children
BILATERAL TUMORS:
                     Bilateral tumors were seen in 8% of girls in the POG/CSG series34.Most of 
them were benign teratomas. For girls with bilateral tumors, careful evaluation of both 
the ovaries should be done to identify the possibility of organ sparing surgery on the 
lesser  involved  side.  Benign  teratomas  mostly  show  a  well  demarcated  plane  of 
separation from the normal parenchyma of the ovary. This makes enucleation without 
violation of the tumor capsule possible in such situations.
TUMOR MARKERS:
                     Germ cell tumors are associated with various biological markers24.They 
are useful  in the identification and management  of  these tumors.  Of these,  αFP and 
βHCG are most readily measured.
                    αFP is an α1 globulin, which is the predominant serum binding protein in 
the  fetus.  It  is  produced by the  fetal  liver,  gastrointestinal  tract  and yolk  sac.  Peak 
concentrations are demonstrated at 12-14 wks of gestation. The levels fall progressively 
after birth to plateau at the normal level of 10 ng/dl. at one year of age. The half life is 
5-7 days. Raised levels are seen in endodermal sinus tumors or embryonal carcinomas. 
Following successful removal of the tumour, progressive fall in levels occur. But, abrupt 
escalation can occur in chemotherapy induced tumor lysis.  Abnormal levels are also 
seen  in  pancreatic,  lung,  liver  and  gastrointestinal  malignancies  as  also  in  benign 
conditions  causing  altered  liver  function  like  hepatitis  or  cholestasis  secondary  to 
exposure  to  general  anaesthesia,phenytoin  or  methotrexate.  In  such  situations, 
measurement of the ratio of concavalin αFP binding to the unbound fraction helps to 
detect if the source is from the tumor cells.
                       βHCG is a glycoprotein produced by the placental syncitiotrophoblasts. It 
has a short half life of 20-30 hrs. So it disappears rapidly following disappearance of 
tumor. <5mIU/ml. can be detected in the serum of healthy individuals. Raised levels are 
noted  in  choriocarcinomas  or  clones  of  syncitial  trophoblastic  giant  cells  seen  in 
germinomas  and  adult  embryonal  carcinomas.  Post  chemotherapy  lysis,  iatrogenic 
hypogonadism due to raised levels of leutinising hormone that causes cross-reactivity, 
multiple myeloma and cancers of the liver, breast, lung and bladder also cause rise in 
titres.
                    LDH is a glycolytic enzyme used in assay of germ cell tumors. It is, 
however, hampered by the lack of specificity for any histological subtype. Increased 
levels are noted in dysgerminomas.
                   CA125 related to the tissues of the coelomic epithelium and Mullerian ducts 
is of value in ovarian tumors of epithelial and stromal origin.18
                             Since germinomas and embryonal carcinomas have no reliable serum markers 
and 20% of ovarian masses are malignant, the current recommendation is to approach all 
ovarian neoplastic masses in girls as if it were malignant.
PATTERN OF TUMOR MARKERS IN OVARIAN MALIGNANCIES
IMAGING:
                    USG is the initial modality of choice in the evaluation of potential ovarian 
pathology in all  age groups.  Though accuracy in differentiating between benign and 
malignant lesions has not yet been established, fairly reliable sonographic characteristics 
are present which point to a malignant process.
                    Highly echoic solid components without demonstrable or measurable inner 
wall28 and the presence of papillae3 are strongly suggestive of malignancy.
                    CT &MRI are useful when the origin of the pelvic mass cannot be assessed 
by  ultrasound18.  Focal  solid  components  with  occasional  cystic  areas  and  coarse 
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calcifications are markers for caution. Direct extension into other pelvic structures or 
distant sites like the liver or lung can also be assessed by CT. MRI is also well suited for 
pelvic lesions owing to its superior tissue contrast resolution.14
FIGO STAGING OF OVARIAN TUMORS:
STAGE EXTENT OF DISEASE
0 No evidence of primary tumor
I
IA
Tumor confined to ovaries
Tumor limited to one ovary, capsule intact.
No tumor on ovarian surface.
No malignant cells in ascites or peritoneal washings.
IB Tumor limited to both ovaries, capsule intact.
No tumor on ovarian surface.
No malignant cells in ascitic or peritoneal washings
IC Tumor  limited  to  one  or  both  ovaries,  with  any  of  the 
following:
Capsule ruptured, tumor on ovarian surface, malignant cells 
in ascites or peritoneal washings.
II
IIA
IIB
IIC
Tumor involves one or both ovaries with pelvic extension
Extension to or implants on the uterus or tubes or both.
No malignant cells in ascites or peritoneal washings.
Extension to other pelvic organs.
No malignant cells on ascites or peritoneal washings
IIA  or  IIB  with  positive  malignant  cells  in  acsites  or 
peritoneal washings.
III
IIIA
IIIB
IIIC
Tumor involves one or both ovaries with microscopically 
confirmed  peritoneal  metastasis  outside  the  pelvis  or 
regional lymph node metastasis.
Microscopic peritoneal metastasis beyond the pelvis.
Macroscopic peritoneal metastasis beyond the pelvis 2cm. 
or less in greatest dimension.
Peritoneal metastasis beyond the pelvis more than 2cm.
 in greatest dimension or regional lymph node 
metastasis
IV Distant metastasis beyond the peritoneal cavity.
CHILDREN’S ONCOLOGY GROUP STAGING OF 
OVARIAN GERM CELL TUMORS
STAGE EXTENT OF DISEASE
I Limited to ovary or ovaries, peritoneal washings negative 
for malignant cells
No  clinical,  radiologic  or  histologic  evidence  of  disease 
beyond the ovaries
Tumor markers normal after appropriate post surgical half 
life decline
Presence  of  gliomatosis  peritonei  does  not  upstage  the 
tumor
II Microscopic  residual  or  positive  lymph  nodes(<2cm  as 
measured by the pathologist)
Peritoneal washings negative
Tumor markers positive or negative
Gliomatosis peritonei upstages the tumor
III Lymph  node  with  malignant  metastatic  nodule(>2cm  as 
measured by the pathologist)
Gross residual or biopsy only
Contiguousvisceral 
involvement(omentum,intestine,bladder)
Peritoneal washings positive for malignant cells
Tumor markers positive or negative
IV Distant metastasis,including liver
TREATMENT  : 
SURGERY:
                  Surgery is the mainstay of successful treatment. It involves complete tumor 
removal with conservation of pelvic structures. Revised surgical procedural guidelines 
as published by the Intergroup Study in 20044 include:
• Collection of ascitic fluid or washings (in the absence of ascites) on entering the 
peritoneal cavity.
• Examination of the peritoneal surface with biopsy or excision of any nodules.
• Examination  and  palpation  of  lymph  nodes  in  the  retroperitoneum (iliac  and 
aorto-caval) with sampling of any firm or enlarged nodes.
• Inspection and palpation of the omentum with removal,  if  any, of adherent  or 
abnormal areas noted.
• Inspection and palpation of the contralateral ovary with biopsy of any suspicious 
areas.
• Complete  removal of the tumor bearing ovary,  without violation of  the tumor 
capsule in situ.
• Sparing the Fallopian tube if it is not adherent.
For tumors that are apparently invading neighbouring structures, initial biopsy only is 
recommended.  PEB chemotherapy  is  highly  effective  in  that  it  allows  for  tumor 
shrinkage.  This  opens  up  the  possibility  of  fertility  sparing  post  chemotherapy 
resection.
LAPAROSCOPY IN TUMOR RESECTION:
              A word of caution in the use of laparoscopy4 in ovarian malignancies is 
prudent. Key components in staging like ascitic cytology, inspection of the pelvic 
peritoneum,  diaphragmatic  surfaces  and  omentum  is  possible.  But  palpation  of 
retroperitoneal nodes and intact delivery of the specimen, which are equally critical, 
prove difficult.
CHEMOTHERAPY :
              On the basis of testicular cancer experiences of Einhorn and Donahue, 
cisplatin,  bleomycin and vinblastine were made available for germ cell  tumors in 
1980.Advantages appeared to be the increased efficacy of cisplatin. The regime also 
required  a  shorter  course  than  the  standard  two  year  schedule  of  vincristine, 
cyclophosphamide and actinomycin–D. However,  increased myelosuppression and 
peripheral neuropathy occurred due to the combination of cisplatin and vinblastine. 
There was also a 2% risk of bleomycin induced pulmonary fibrosis.
               During the same year that the report was published, etoposide was 
introduced. By eliminating vinblastine and decreasing the total cumulative dose of 
bleomycin, PEB regime thus had the advantage of improving survival with an overall 
reduction in toxicity.
                 An eight year study from the COG that closed in 1992 evaluated PEB31. 91 
of 93 patients were free of disease after a mean follow up of 38.6 months. Moreover, 
the  risk  of  chemotherapy  induced complications  is  low vis  a  vis  the  efficacy  of 
platinum based regimes32.
                 Currently ongoing phase III COG trials5 initiated in November 2003 
classifies germ cell tumors into 3 risk groups based on the nature of the primary and 
the stage. Low risk stage I ovarian tumors appear to do well with complete resection 
alone. Intermediate risk groups included stage II and III, who showed a 90% 3 year 
survival, are now being treated with modified shortened PEB regimes of 3 cycles 
every  21  days.  Therapy  is  discontinued  upon  complete  pathologic  response  and 
normal tumor marker values. High risk and recurrent tumors are being bombarded 
with high dose chemotherapy with autologous stem cell transplantation.
UNCLASSIFIED MALIGNANCIES:
                These are a heterogenous group26 with uniformly poor survival. Though 
predominantly in older age groups, reports of rhabdomyosarcomas in children <20 
years  have  been  published.  Outcome  is  poor  owing  to  the  advanced  stage  at 
diagnosis.
                    Stromal and low grade endometrial sarcomas of the ovary arising from 
foci of ovarian endometriosis, albeit rare, have been reported in the second decade. 
Treatment  of  these  advanced  locally  infiltrating  tumors  is  radical  with  total 
abdominal  hysterectomy  with  bilateral  salpingo-oophorectomy  followed  by 
chemotherapy and radiation.
METASTATIC TUMORS:
                Though rare,  ovaries  may be the site  of  metastasis26 either  by 
haematogenous, lymphatic, transcoelomic or direct spread. Just like the testis, it may 
harbour leukaemic deposits. Others include primaries from the stomach, colorectum, 
breast and rarely Wilms’ or deposits from neuroblastomas.
IMPACT OF TREATMENT ON OVARIAN FUNCTION:
               Survival rates of prepubertal gynaecological  cancers are constantly 
improving. The other side of the coin, nevertheless, is that these life saving treatment 
schedules may carry the risk of infertility. Though chemotherapy may cause oocyte 
and follicular loss25 and induce premature ovarian failure, most studies have shown 
normal reproductive potential in the long run16,35. Reports between the two schools 
are controversial. In a study of patients who underwent fertility preserving surgery, 
Holzer16 et al. who followed these women over 20 years showed that 23 of the 26 
patients never conceived; indicating that fertility was seriously affected. However, 
Zonagnola’s  35paper  showed  quite  the  opposite  with  females  maintaining  normal 
ovarian function and reproductive potential after chemotherapy.Animal models have 
shown that  although there  are  decreased  estrogen levels,  reduced  litter  sizes  and 
earlier menopause, there is adequate compensation by the contralateral ovary.Thus 
fertility rates appear to be the same as age matched controls.
FUTURE TRENDS:
                 Further definition of biologic features is required to help select those 
patients who may not respond to first line chemotherapeutic regimes. Differentiating 
characteristics of adult and pediatric tumors that predict response to standard therapy 
is also needed. This also involves further insights into the genetics of these tumors.
           Although there may exist  unknown repair mechanisms after anticancer 
treatment,  biological  ovarian  age  in  cancer  survivors  appears  10  years  ahead  of 
chronological  age22.  Hence  attempts  at  oocyte  or  embryo  cryopreservation16 or 
vitrification are under trial. This is particularly indicated in cancers where treatment 
cannot be delayed for ovarian stimulation or the tumors which are hormone sensitive. 
Until  now, by these,  only one human birth has been reported.  More importantly, 
critical issues like graft survival or the potential risk of transmission of malignant 
cells have to be addressed.
MATERIALS AND METHODS
                 A retrospective review of all ovarian malignancies treated at the Institute 
of Child Health between January 2001 and January 2006 was done. 
               48 patients with ovarian malignancies were identified. Defective case 
records of 5 patients owing to lack of essential data were excluded from the study. A 
structured proforma was prepared(vide infra).
               The age at presentation, symptoms and nature of presentation were noted. 
The efficacy of imaging in pointing at the malignant nature of the lesion was also 
assessed. The tumor marker elevations vis-à-vis the histopathology was correlated.
                  Intraoperative features of the tumor, capsular integrity and associated 
anomalies were recorded. Pathological reports on gross and microscopic features of 
the tumor were compared with the intraoperative findings.
                  All patients received chemotherapy with a platinum based regime.The 
schedule followed at our Institute was
Bleomycin  15 units /sq.m. weekly for 5 weeks
Etoposide    100 mg/sq.m./day X 3 days
Cisplatin      20 mg/sq.m./day X 3 days
The latter two being administered once in 21 days for 4 cycles.
Postoperatively and thereafter periodic tumor marker estimation with imaging was 
carried out.
                      Gonadal functions of these patients were evaluated during their visits to 
the  tumor  board  review  meets.At  these  visits,history  and  clinical  examination 
regarding the age at menarche, adequacy of secondary sexual characters and nature 
of menstrual cycles were noted.Hormonal estimation,if indicated,was done.
                    Fertility could not be assessed as these children had not yet reached the 
age at which the full impact of the treatment could be checked.
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RESULTS
                  Of the total no. of ovarian tumors, 62.79% presented between 9 and 11 
years confirming that these malignancies are more common in adolescent girls.
                     13.9% of the total presented with acute abdominal symptoms. In this 
setting, the pre operative diagnosis was often confused with peritonitis or appendicular 
pathology.  Yet  others  had  mass  abdomen  and  insidious  pain  as  the  predominant 
complaints.This  was  similar  to  other  reports  in  literature7.All  the  4  patients  who 
presented with precocious puberty had embryonal carcinoma.
                      Ultrasonogram had a sensitivity of 83% and a specificity of 84% in 
pointing at a potential malignancy in our study.This corroborates with Tuladhar et al28. 
who reported a sensitivity of 85.7% and specificity of 83.8% of ultrasound as the initial 
imaging modality in ovarian malignancy.Of all the parameters, we found that the size of 
the  lesion  was  an  important  parameter;  the  larger  the  dimension,  the  higher  the 
possibility of malignancy. A similar finding was stated by Darrell et al8. that >10 cm. 
lesions were more likely to be malignant.
                     Pre-operative evaluation of the tumor markers were done for all cases in 
the elective setting. The pattern of rise conformed to that found in literature.
                   Epithelial malignancies in reviews have accounted for   < 15% of pediatric 
ovarian malignancies8.Our series had none.
                   The most common histology was mixed tumors with teratoma elements in 
contrast to literature which states dysgerminoma to be the most frequent20.
                   Bilateral tumors were seen in 8% of girls in the POG series 34.Our study had 
none.
                 The presentation of 13.9% in the acute setting ( 11% in the Intergroup Study)4 
produces the need for emergency operative intervention.This carries the problems of the 
lack  of  complete  imaging  information  and the  disadvantage  of  the  unavailability  of 
tumor markers. In such situations, as there are no clear cut gross characteristics to detect 
malignancy,  ovarian lesions  should  be treated  as  potentially  malignant,  until  proved 
otherwise4.This  avoids  the  loss  of  valuable  information  which  affects  staging  and 
thereby,  treatment  if  inadequate  surgical  staging  measures  are  undertaken  during 
exploration.
                Tumor sizes ranged between 3 and 17 cms. The recommended surgical 
guidelines were not followed completely in all cases. The greatest deficit was the lack of 
appropriate lymph node sampling. Only 9% of them were sampled, all being negative 
for malignancy.
                    Preoperative rupture of the tumor capsule or accidental disruption during 
operative manipulation occurred in 3 patients. Surprisingly, this did not affect long term 
survival.
                    Samples of ascitic fluid and peritoneal washings were obtained in 38 
patients.Of these 31.5% were positive for malignancy.
                 Omentectomy was done in 36 patients. Histology perusal revealed that 
30.25%  showed  malignant  infiltration.  The  others  were  normal  except  one  which 
showed an inflammatory pathology.
                     Though the contralateral ovary was examined in all cases, it was biopsied 
in  only  2.  Both  were  negative  for  malignant  deposits.  Some  of  the  co-existent 
abnormalities noted were agenesis of  the opposite ovary and a follicular  cyst  which 
regressed during the follow up period.
                     The surgeon’s assessment of capsular integrity was not found to be reliable. 
This reaffirms Billimire et al4 viewpoint that the pathologist has to examine the intact 
specimen to ensure that staging is not compromised.
                      2 large tumors which were adherent to the surrounding structures caused 
surgical difficulty. There was no evidence of local invasion to the neigbouring viscera. 
These tumors were resected primarily. There was greater blood loss and the duration of 
surgery was prolonged. However, they could be removed in toto without resecting any 
vital  organ. 1 of these girls subsequently presented with adhesive bowel obstruction, 
necessitating resection anastomosis.
                     Stage grouping was done from the available information. The distribution 
of the various stages was as follows:
 Stage I - 51.16%, Stage II – 16.27%, Stage III – 27.9%, Stage IV – 4.65%.
                    Based on the success of surgery alone in stage I testicular tumors in boys 
and the  European experience with surgery only  for  stage  I  ovarian tumors,  COG is 
presently  evaluating  the  same.  In  our  study,  we  administered  chemotherapy  for  all 
stages. The schedule followed was the PEB regime. It resulted in a complication rate of 
13.95% vis a vis that of  20%10 in literature. The most recent intergroup trial for high 
risk malignant germ cell tumors in children from POG and CCG, 2% died of toxicity 
from therapy6.Our series had none. However, morbidity in the form of liver cell and 
renal failure was noticed in our patients.
                      Of the 43 patients enrolled in our study, 4 have lost follow up. 2 have since 
succumbed  to  the  disease.  9  girls  have  finished  5  years  since  the  completion  of 
treatment.The  5  year  survival  rate  was  81.8%  (all  stages  included).The  maximum 
survivors were in stage I  and stage II .Stage IV carried a dismal prognosis with no 
patient  completing 5 year  follow up.  Reviews quote  a 95% survival  for  stage I  and 
93.3% for stage IV.4    Effective multiagent chemotherapy is probably the reason for these 
excellent survival rates.
                Some studies however quote a lower survival of 54.8%  for stage IV.27 In our 
study,  both  the  patients  in  stage  IV  presented  with  advanced  disease  with  distant 
metastasis.  Moreover,one patient  was noncompliant with the chemotherapy schedule. 
Those  with  advanced  disease  and  noncompliant  with  the  treatment  regime  are  at 
increased  risk  of  treatment  failure  and  death,  thus  stressing  the  need  for  patient 
education.
                  Of those patients followed up after completion of treatment,  10 girls have 
since  entered  the  peripubertal  age.1  had  a  documented  agenesis  of  the  contralateral 
ovary at the time of surgery. All the others except one patient have attained menarche. 
This  correlated  with  Noczynska’s21etal  observation.  They  stated  that  pubertal 
development  and  onset  is  normal  despite  unilateral  ovariectomy.  The  mean  age  at 
menarche  was  12.8  years.  The  menstrual  cycles  are  regular  and  there  has  been  an 
adequate development of secondary sexual characters. The lone patient who has not yet 
attained  menarche  underwent  hormonal  estimation  which  was  normal.  She  is  now 
undergoing gynecological evaluation for the same.
                         All these patients have not yet reached the age when impact on 
reproductive  potential  can  be  studied.  Nevertheless,  despite  series  quoting  normal 
fertility patterns, we offer a guarded prognosis and a word of caution.
 
           
CONCLUSIONS
 Review of ovarian tumors at  our institute showed that  germ cell  tumors are highly 
treatable solid malignancies in the prepubertal age group.
• Most  of  these  tumors  present  early  making local  control  easy.  This  is  further 
boosted by effective platinum based chemotherapy.
• As seen in our study,epithelial ovarian malignancies are rare in children.
• Ultrasonogram has a fairly good degree of reliability as an indicator of potentially 
malignant lesions. Nevertheless, it should be used only as an adjunct and not as 
the primary modality for diagnosis.
• In the acute setting, to prevent loss of significant information which might affect 
staging  and treatment,  it  is  better  to  treat  all  suspicious  lesions  as  potentially 
malignant, until proved otherwise.
• The  onset  of  puberty  following chemotherapy is  comparable  with  that  of  age 
matched controls.
• With the advent of newer agents and less toxic regimes, further trials are required 
to assess their impact on fertility. Their effects on the reproductive potential is a 
critical issue that needs to be addressed in the long run. Till such time that more 
light is thrown on this ,caution has to be exercised.
• To quote Larsen et al19.,“ though there may exist  unknown repair mechanisms 
after anticancer treatment, the biological age of the ovaries is 10 years ahead of 
the chronological age.” This important factor is to be stressed in the counseling of 
these patients.
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PROFORMA
NAME:                            AGE:                              I.P.NO.
Date of admission:
Date of surgery:
Date of discharge:
Informant:                                                              Reliability:
PRESENTING COMPLAINTS:
Presentation: Acute –
                      Chronic-
Symptoms & duration:
                 Pain abdomen
                 Abdominal distension
                 Mass abdomen
                 Loss of appetite
                 Loss of weight
                 Urinary symptoms:
                 S/O precocious puberty: bleeding per vaginum
                                                        breast development
                                                        Pubic/axillary hair growth
     Other symptoms
FAMILY HISTORY:     H/o malignancy
EXAMINATION:
 Pallor
Adenopathy
Breast bud development
Axillary  pubic hair distribution
P/A: Palpable mass (associated details)
         Associated organomegaly
P/R:
INVESTIGATIONS:
Tumor markers: αFP
                             βHCG
USG abdomen: Size
                          Solid/cystic
                          Presence of papillae
                          Other features
CT scan:
CXR
 OPERATIVE DETAILS:
  Preoperative diagnosis:
  Tumor characteristics:  Torsion
                                         Size
                                         Capsular integrity
                                         Intra operative spill
                                         Fallopian tube involvement
   Other features: Ascites/peritoneal washings
                           Omentectomy
                            Retroperitoneal lymph node sampling
                            Liver metastasis
                            Peritoneal and diaphragmatic surfaces
                            Contralateral ovary
                           Any other anomalies
PATHOLOGY: 
                          Gross: Tumor size / weight
                             Histopathology: Tumor type/capsule integrity
                                                          Nodal status
                                                           Omental histology
                                                           Ascitic fluid cytology 
POST OPERATIVE COMPLICATIONS:
Surgical:
Chemotherapy related:
STAGING :
FOLLOW UP  : 
Age at menarche
Nature of the menstrual cycles: Duration
                                                   Periodicity
                                                   Nature of flow
Breast development
Axillary & pubic hair development
Status of the contralateral ovary on imaging
Tumor markers(if elevated pre operatively)
Hormonal estimation (if done)
DURATION OF FOLLOW UP  : 
                       
 Table 1: Age distribution of ovarian malignancies
  
AGE NO.OF PATIENTS PERCENTAGE
<5 YEARS 05 11.62
5-8 YEARS 07 16.27
9-11 YEARS 27 62.79
>12 YEARS 04 9.30
Table 2: Symptoms at presentation
SYMPTOM NO.OF PATIENTS PERCENTAGE
Acute abdomen 06 13.91
Mass abdomen 29 67.44
Pain abdomen 31 72.09
Loss
of weight/appetite
25 58.13
Precocious puberty 04 9.30
Table 3: Tumor marker estimation
HISTOLOGY αFP βHCG
Dysgerminoma _ _
Teratoma +/- _
Yolk sac tumor + _
Mixed germ cell +/- _
Embryonal _ +
Table 4: Intra operative staging
PROCEDURE NO.OF 
PATIENTS
PERCENTAGE
Retroperitoneal lymph node sampling 04 9.30
Biopsy of the opposite ovary 02 4.65
Ascitic/peritoneal washings 38 88.31
Omentectomy 36 83.7
Adhesions to surrounding structures 02 4.65
Table 5: Staging of ovarian tumors
STAGE NO.OF PATIENTS PERCENTAGE
I 22 51.16
II 07 16.27
III 12 27.9
IV 02 4.65
Table 6: Histology of ovarian tumors
HISTOLOGY NO. OF PATIENTS PERCENTAGE
Yolk sac tumor 11 25.58
Dysgerminoma 08 18.60
Teratoma 07 16.27
Mixed germ cell tumor 13 30.23
Embryonal 04 9.30
Table 7: Complications
COMPLICATION NO. OF PATIENTS PERCENTAGE
Febrile neutropenia 03 6.97
Jaundice 02 4.65
Renal failure 01 2.32
Adhesive obstruction 01 2.32
Table 8: Period of follow up and survival
STAGE I
NO.OF YEARS NO.OF PATIENTS PERCENTAGE
5 YEARS 04 (n=6) 66.66
4 YEARS 02 (n=2) 100
3 YEARS 02 (n=2) 100
2 YEARS 03 (n=3) 100
1 YEAR 02 (n=2) 100
STAGE II
NO.OF YEARS NO.OF PATIENTS PERCENTAGE
5 YEARS 05 (n=5) 100
4 YEARS 04 (n=6) 66.66
3 YEARS 04 (n=4) 100
2 YEARS 03 (n=3) 100
1 YEAR 01 (n=1) 100
STAGE III
NO.OF YEARS NO.OF PATIENTS PERCENTAGE
5 YEARS NIL NIL
4 YEARS 03 (n=4) 75
3 YEARS 01 (n=2) 50
2 YEARS 03 (n=3) 100
1 YEAR 02 (n=2) 100
NOTE:  No survivors in stage IV.
               4 patients have lost follow up
               2 have succumbed to the disease
